Stock Analysis
ADMA Biologics, Inc. (ADMA) Stock Analysis
ADMA Biologics, Inc. (ADMA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
ADMA Biologics, Inc. (ADMA) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 91/100. Risk is the weakest current factor at 56/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ADMA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $13.68 |
| AIQ Score | 78/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $3.06B |
| P/E Ratio (TTM) | 17.32 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $0.22 |
| Revenue (Q3 FY2026) | $141.1M |
| Dividend Yield (TTM) | 0.00% |
| Beta | -0.09 |
| Volume | 4.16M |
| 52-week range | $7.21-$20.46 |
| RSI 14 | 71.04 |
| 50-Day SMA | $10.58 |
| 200-Day SMA | $10.73 |
| Analyst Price Target | $18.00 |
| Next Earnings | Feb 24, 2027 |
ADMAADMA Biologics, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum91
- Value80
- Quality72
- Risk resilience56
- Sentiment—
ADMA Stock Analysis Summary
ADMA Biologics, Inc. (ADMA) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 91/100. Risk resilience is the weakest current factor at 56/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, ADMA has AIQ Score of 78/100 with Momentum base of 91/100 and fading Risk resilience at 56/100. Wait for component alignment before adding exposure.
Momentum (91/100) leads while Risk resilience (56/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 3.32% stock move · ADMA classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ADMA Bullish or Bearish Right Now?
ADMA currently has a bullish overall setup. Momentum is the strongest factor at 91/100, while Risk Resilience is weakest at 56/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 72/100.
- - Momentum is constructive at 91/100.
- - Price is +29.36% above its 50-day SMA.
- - Analyst target implies +31.58% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (38 vs 6).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
ADMA's Technical Analysis Consensus is currently Strong Buy, with 38 buy, 2 neutral, and 6 sell votes. ADMA's 14-day RSI is 71.04, which places the stock in an overbought momentum range. ADMA's beta is -0.09, indicating lower market sensitivity than the broad market.
What Changed in ADMA?
The largest recent change in ADMA is Momentum moving up by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the ADMA Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ADMA Decision Framework
Public evidence layers, setup checks, and risk context for ADMA Biologics, Inc..
ADMA Biologics, Inc. (ADMA) Stock Analysis
ADMA Biologics, Inc. has an AIQ Score of 78/100 in a Bullish regime. Momentum is strongest at 91/100. Beta is -0.09, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ADMA is in a Bullish AIQ regime with score 78/100. |
| Signal Conflict | The primary conflict is that momentum leads at 91/100 while risk lags at 56/100. |
| Factor Evidence | Momentum 91/100 · Value 80/100 · Quality 72/100 · Risk 56/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 91/100.
Momentum is 91/100 and RSI (14) is 71.0.
ADMA is in a Bullish regime at 78/100.
Risk factor is 56/100 with beta -0.09 and annual volatility 58.93%.
Current conflict: momentum leads at 91/100 while risk lags at 56/100.
ADMA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ADMA Fundamentals
ADMA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ADMA Technical Analysis
ADMA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ADMA Stock Catalysts
Track ADMA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ADMA Dividend Analysis
ADMA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ADMA Financial Data
ADMA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ADMA Risk Analysis
ADMA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ADMA Stock News
ADMA stock news, market tone, recent headlines, and catalyst context.
ADMA vs Biotechnology Peers
Current peer cohort: ADMA · AGIO · ALMS · AMLX · ANAB. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ADMA Current stock | 78/100 | 80/100 | 91/100 | 56/100 | -0.01 | 58.93% | Current |
| AGIO Agios Pharmaceuticals, Inc. | 56/100 | 52/100 | 61/100 | 47/100 | 0.07 | 79.96% | ADMA vs AGIO |
| ALMS Alumis Inc. | 20/100 | — | 13/100 | 20/100 | 0.65 | 137.60% | ADMA vs ALMS |
| AMLX Amylyx Pharmaceuticals, Inc. | 78/100 | — | 90/100 | 48/100 | 1.35 | 87.03% | ADMA vs AMLX |
| ANAB AnaptysBio, Inc. | 56/100 | 74/100 | 36/100 | 46/100 | 0.78 | 64.84% | ADMA vs ANAB |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for ADMA: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ADMA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ADMA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ADMA Stock FAQ
What is ADMA stock price today?
ADMA Biologics, Inc.'s current stock price is $13.68. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ADMA bullish or bearish right now?
ADMA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ADMA's market cap?
ADMA's market cap is $3.06B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ADMA's current P/E ratio?
ADMA's current P/E ratio is 17.32 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ADMA's RSI?
ADMA's 14-day RSI is 71.04 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ADMA above its 50-day and 200-day moving averages?
ADMA is 29.36% from its 50-day SMA and 27.55% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ADMA's next earnings date?
ADMA's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ADMA pay a dividend?
ADMA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.